EP3529360
Aðferðir til að fyrirbyggja hjarta- og æða-atburði með prótínminnkun á próprótíns-klippi-subtílisín-kexín 9 (PCSK9)
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.10.2017EP published:
17.4.2024EP application number:
17800976.7
EP translation filed:
8.7.2024Grant published:
15.9.2024EPO information:
European Patent Register
Max expiry date:
17.10.2037Expiry date:
17.10.2026Next due date:
31.10.2026
Title in English:
METHODS FOR PREVENTING CARDIOVASCULAR EVENTS THROUGH PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) PROTEIN REDUCTIONLanguage of the patent:
English
Timeline
Today
18.10.2017EP application
17.4.2024EP Publication
8.7.2024Translation submitted
15.9.2024Registration published
17.10.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
WIJNGAARD, PeterAddress:
Parsippany NJ 07054, US
Name:
KALLEND, DavidAddress:
Parsippany NJ 07054, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201662409816 PDate:
18.10.2016Country:
US
Number:
201662422028 PDate:
14.11.2016Country:
US
Number:
201762472525 PDate:
16.3.2017Country:
US
Number:
201762550426 PDate:
25.8.2017Country:
US
Classification
Categories:
C12N 15/113, A61K 31/713
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 23.9.2024
Expires: 17.10.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 2.10.2025
Expires: 17.10.2026
Payer: Árnason Faktor ehf.